Farydak(panobinostat)
Farydak (panobinostat) is a small molecule pharmaceutical. Panobinostat was first approved as Farydak on 2015-02-23. It is used to treat multiple myeloma in the USA. It has been approved in Europe to treat multiple myeloma. It is known to target histone deacetylase 1, histone deacetylase 8, histone deacetylase 2, histone deacetylase 4, histone deacetylase 9, histone deacetylase 6, histone deacetylase 3, and histone deacetylase 7.
Download report
Favorite
Novartis Pharmaceuticals
Commercial
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Panobinostat lactate
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| FARYDAK | Secura Bio | N-205353 DISCN | 2015-02-23 | 3 products, RLD |
Hide discontinued
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| farydak | New Drug Application | 2021-07-27 |
Agency Specific
FDA
EMA
No data
HCPCS
No data
Clinical
Clinical Trials
146 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Breast neoplasms | D001943 | EFO_0003869 | C50 | 7 | 5 | — | — | — | 9 |
| Non-hodgkin lymphoma | D008228 | C85.9 | 4 | 2 | — | — | — | 6 | |
| Large b-cell lymphoma diffuse | D016403 | C83.3 | 1 | 6 | — | — | — | 6 | |
| Prostatic neoplasms | D011471 | C61 | 4 | 2 | — | — | — | 5 | |
| Precursor cell lymphoblastic leukemia-lymphoma | D054198 | C91.0 | 3 | 3 | — | — | — | 5 | |
| Glioma | D005910 | EFO_0000520 | 3 | 3 | — | — | — | 5 | |
| Lymphoma | D008223 | C85.9 | 3 | 4 | — | — | — | 5 | |
| Melanoma | D008545 | 4 | 1 | — | — | — | 4 | ||
| Diffuse intrinsic pontine glioma | D000080443 | 3 | 2 | — | — | — | 4 | ||
| Leukemia | D007938 | C95 | 2 | 3 | — | — | — | 4 |
Show 32 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Neoplasms | D009369 | C80 | 12 | — | — | — | — | 12 | |
| Non-small-cell lung carcinoma | D002289 | 6 | — | — | — | — | 6 | ||
| Liver neoplasms | D008113 | EFO_1001513 | C22.0 | 2 | — | — | — | — | 2 |
| Head and neck neoplasms | D006258 | 2 | — | — | — | — | 2 | ||
| Lung neoplasms | D008175 | C34.90 | 2 | — | — | — | — | 2 | |
| Brain neoplasms | D001932 | EFO_0003833 | C71 | 2 | — | — | — | — | 2 |
| Castration-resistant prostatic neoplasms | D064129 | 1 | — | — | — | — | 1 | ||
| Anemia | D000740 | EFO_0004272 | D64.9 | 1 | — | — | — | — | 1 |
| Leukemia myeloid chronic atypical bcr-abl negative | D054438 | C92.2 | 1 | — | — | — | — | 1 | |
| Thrombocytosis | D013922 | D75.83 | 1 | — | — | — | — | 1 |
Show 13 more
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | PANOBINOSTAT |
| INN | panobinostat |
| Description | Panobinostat is a hydroxamic acid obtained by formal condensation of the carboxy group of (2E)-3-[4-({[2-(2-methylindol-3-yl)ethyl]amino}methyl)phenyl]prop-2-enoic acid with the amino group of hydroxylamine. A histone deacetylase inhibitor used (as its lactate salt) in combination with bortezomib and dexamethasone for the treatment of multiple myeloma. It has a role as an EC 3.5.1.98 (histone deacetylase) inhibitor, an antineoplastic agent and an angiogenesis modulating agent. It is a hydroxamic acid, a member of cinnamamides, a secondary amino compound and a methylindole. It is a conjugate base of a panobinostat(1+). |
| Classification | Small molecule |
| Drug class | enzyme inhibitors: histone deacetylase inhibitors |
| Image (chem structure or protein) | |
| Structure (InChI/SMILES or Protein Sequence) | Cc1[nH]c2ccccc2c1CCNCc1ccc(/C=C/C(=O)NO)cc1 |
Identifiers
| PDB | 5EF8 |
| CAS-ID | 404950-80-7 |
| RxCUI | 1603350 |
| ChEMBL ID | CHEMBL483254 |
| ChEBI ID | 85990 |
| PubChem CID | 6918837 |
| DrugBank | DB06603 |
| UNII ID | 9647FM7Y3Z (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
HDAC1
HDAC1
HDAC8
HDAC8
HDAC2
HDAC2
HDAC4
HDAC4
HDAC9
HDAC9
HDAC6
HDAC6
HDAC3
HDAC3
HDAC7
HDAC7
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 7,089 documents
View more details
Safety
Black-box Warning
Black-box warning for: Farydak
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
5,994 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more